VTP50469
VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity[1][2].
Product Specifications
CAS Number
2169916-18-9
Product Name Alternative
GCA-1
UNSPSC
12352005
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vtp50469.html
Purity
99.69
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N(C(C)C)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(C)=O)CC5)CC4)C3
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.82
References & Citations
[1]Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36 (6) :660-673.e11.|[2]Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC042620-500 1x 500 µL
Cyclin D2 (CCND2/2620), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941266-100 1x 100 µL
Cytokeratin 8 (KRT8) (B22.1), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681660-500 1x 500 µL
Cytokeratin 1 (Suprabasal Keratinocyte Marker) (LHK1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details